Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770931 | 0.79 | PGR (0.56) | PGR | |
| SCHEMBL3985122 | 0.73 | PGR (0.45) | PGR | |
| SCHEMBL7051390 | 0.71 | PGR (1.00) | PGR | |
| SCHEMBL7487504 | 0.70 | PGR (0.55) | PGR | |
| SCHEMBL18481933 | 0.68 | SIRT2 (0.36) | GABRA1GABRB2GABRA5GABRA3GABRA2 | |
| SCHEMBL18466762 | 0.68 | GABRA1 (0.37) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL6539867 | 0.67 | AR (0.38) | PGRCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL6766774 | 0.66 | PGR (0.60) | PGR | |
| SCHEMBL30825149 | 0.65 | GAA (0.47) | GABRA1GABRB2OPRM1OPRD1 | |
| SCHEMBL29185410 | 0.65 | GAA (0.47) | GABRA1GABRB2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693103-B2 | CONTRACEPTION, TREATMENT OF FIBROIDS, ANTICARCINOGENIC AND -TUMOR AGENTS (ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER), AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY; BENIGN PROSTATIC HYPERTROPHY; ADENOCARCINOMAS | WYETH | 2004-02-17 | — | — | US | disclosed |
| US-6498154-B1 | CONTRACEPTION; PROGESTATIONAL ACTIVE LEVONORGESTREL AND AN ANTIPROGESTIN COMPOUND | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1175404-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173206-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING QUINAZOLINONE AND BENZOXAZINE DERIVATIVES | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066560-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066165-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING QUINAZOLINONE AND BENZOXAZINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | PGR 1/4885CHRNA1 37/4885CHRNG 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.